Cellectis
CLLS | NASDAQ
$1.04
-$0.14 (-11.86%)
At close: Nov 16, 2026, 4:00 PM ET
$1.04
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-11.86%
(1D)No price chart data available for 1D timeframe.
Rating
38.5
-1.5 ptsFundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #562/1021 (Top 55%)
Key Statistics
Market Data
Market Cap $104.76M
1D Range
1.00 1.14
52W Range
0.93 5.35
Valuation (TTM)
PE -1.58
PB 2.55
EV/EBITDA -0.41
Valuation (NTM)
Forward PE N/A
Forward PEG -0.03
Price Target $2.15
Cash Flow
FCF Yield -42.1%
SBC Adj. FCF Yield -44.3%
SBC Impact -5.2%
Margins
Gross Margin 74.7%
Operating Margin -109.3%
FCF Margin -77.9%
Growth (CAGR)
Revenue 3Y | 5Y 50.3% |
-0.1%
Dil EPS 3Y | 5Y 27.0% |
40.1%
FCF 3Y | 5Y -452.4% |
42.0%
Returns
ROA -24.4%
ROE -94.1%
ROIC -41.0%
Financial Health
Net Cash
$112.87M
Current Ratio 1.37
Interest Coverage -7.27
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express ...
Sector Healthcare
Industry Biotechnology
Employees 229
IPO Date Mar 24, 2015
Website www.cellectis.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 12, 2026
EPS
-$0.61
Miss -238.89%
YoY:
-6200.00% REV
$3.76M
Miss -75.89%
YoY:
-89.30%Next Earnings
Mar 4, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
4
Consensus
Hold
Price Target
$2.15
Upside
+106.73%
Buy (1)
Hold (2)
Sell (1)
Add to Watchlist
Select watchlists to add or remove CLLS